Deutsche Bank Upgrades Allstate (ALL) to Buy; Earnings Emerge from Trough
Get Alerts ALL Hot Sheet
Price: $261.41 +0.36%
Rating Summary:
16 Buy, 19 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
16 Buy, 19 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Deutsche Bank upgraded Allstate (NYSE: ALL) to Buy, price target raised $2 to $31.00.
Deutsche analyst says, "After four disappointing years for Allstate--in terms of earnings results and loss of auto marketshare--the outlook and share price for the company's stock looks to have reached a bottom and seems overdone. Investors have become more realistic, if not too pessimistic, about Allstate's earnings power. With a expected ROE of 8%--assuming weather losses continue to be high--its ROE outlook is not that much lower than its peers who trade at a significant premium to Allstate and whose earnings outlooks are meaningfully at risk of being disappointed."
For an analyst ratings summary and ratings history on Allstate click here. For more ratings news on Allstate click here.
Shares of Allstate closed at $26.56 yesterday.
Deutsche analyst says, "After four disappointing years for Allstate--in terms of earnings results and loss of auto marketshare--the outlook and share price for the company's stock looks to have reached a bottom and seems overdone. Investors have become more realistic, if not too pessimistic, about Allstate's earnings power. With a expected ROE of 8%--assuming weather losses continue to be high--its ROE outlook is not that much lower than its peers who trade at a significant premium to Allstate and whose earnings outlooks are meaningfully at risk of being disappointed."
For an analyst ratings summary and ratings history on Allstate click here. For more ratings news on Allstate click here.
Shares of Allstate closed at $26.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
Create E-mail Alert Related Categories
UpgradesRelated Entities
Deutsche Bank, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share